Tuesday, February 2, 2010
Working at the Global Level in China
Multinational trials have become increasingly complex and timelines have lengthened since the European Union Clinical Trial Directive 2001/20/EC went into effect. This has resulted in stakeholders’ need for more staff and ultimately higher costs to run drug development programs in Europe. While stakeholders have anecdotally drawn similar conclusions, a report by The Impact on Clinical Research of European Legislation (ICREL), is now able to provide hard data to back up these claims. The report demonstrates the significant impact of the directive on all stakeholders.
U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009
Pfizer’s Enhanced Clinical Trial Design Saves $100 Million Annually